● AI Equity Research · Healthcare

Teladoc Health, Inc. (TDOC)

AI stock analysis · Health Information Services · Last analyzed Jul 8, 2026

Compass Score

2.0/5

Call

Avoid

Price

$9.14

AI Target

$7.67 -16.1%

AI Analyst Summary

Teladoc Health is a telehealth platform navigating a difficult post-pandemic normalization, with revenue declining 2.5% YoY and the company still loss-making at a -14.1x forward P/E. Management has shown cost discipline with a perfect 4-of-4 recent EPS beat streak, but this reflects margin management rather than growth momentum. The key risk is that the analyst consensus price target of $7.67 sits 16.1% below the current price, signaling material downside according to the Street.

Catalysts

A return to positive revenue growth in telehealth segment driven by chronic care (BetterHelp/Chronic Care) membership stabilization, expected to be disclosed in upcoming quarterly earnings.
Potential strategic review or M&A activity — management has signaled a focus on portfolio optimization, which could unlock value in the BetterHelp mental health unit.
Continued EPS beat in the next quarterly report driven by ongoing cost restructuring and headcount reductions, which could shift analyst sentiment from Hold toward Buy.

Risks

Analyst consensus price target of $7.67 implies ~16% downside from current levels ($9.14), suggesting the Street views the stock as overvalued at current prices.
Sustained revenue contraction (-2.5% YoY) in a competitive telehealth market with increasing pressure from Amazon Clinic, CVS Health, and hospital-at-home programs could accelerate member churn.
Ongoing losses with no clear profitability timeline increase balance sheet risk; any deterioration in cash runway or need for dilutive equity issuance could weigh heavily on the share price.

Fundamentals

Pe N/A (loss-making) · 1.0/5

No trailing P/E available; company is loss-making with a negative forward P/E of -14.1x, indicating no clear near-term path to profitability.

Peg N/A · 2.0/5

PEG ratio unavailable. Combined with negative earnings and declining revenue (-2.5% YoY), growth quality is poor, warranting a below-average score.

Analyst Rating Hold (2.5) · 3.0/5

Consensus sits exactly at 2.5 on the inverted scale (7 Buy / 18 Hold / 0 Sell across 20 analysts), reflecting a broadly cautious but not bearish stance. Maps to a neutral score of 3.

Earnings Trend N/A earnings growth; revenue -2.5% YoY · 2.0/5

No positive earnings growth trend is discernible — the company remains loss-making with slightly declining revenues. While EPS beats are consistent, the underlying trajectory is deteriorating.

Price Target Beat 4 of 4 quarters beat (last 4Q only) · 3.0/5

A perfect 4-of-4 beat rate over the last four quarters is encouraging, but the sample size is limited to four periods. Scored neutrally at 3 per guidelines for insufficient 8-quarter history.

Management Mixed — consistent EPS beats, but declining revenues · 3.0/5

Management has consistently beaten EPS estimates in recent quarters, suggesting cost discipline. However, revenue contraction and sustained losses limit confidence in strategic execution and capital allocation quality.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.